A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study-Reference-Cited by-同舟云学术

A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study

Published:2013-05-16 Issue:10 Volume:72 Page:1613-1620
ISSN:0003-4967
Container-title:Annals of the Rheumatic Diseases
language:en
Short-container-title:Ann Rheum Dis

Author:

Yoo Dae Hyun,Hrycaj Pawel,Miranda Pedro,Ramiterre Edgar,Piotrowski Mariusz,Shevchuk Sergii,Kovalenko Volodymyr,Prodanovic Nenad,Abello-Banfi Mauricio,Gutierrez-Ureña Sergio,Morales-Olazabal Luis,Tee Michael,Jimenez Renato,Zamani Omid,Lee Sang Joon,Kim HoUng,Park Won,Müller-Ladner Ulf

Publisher

BMJ

Subject

General Biochemistry, Genetics and Molecular Biology,Immunology,Immunology and Allergy,Rheumatology

Reference20 articles.

1. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group;Maini;Lancet,1999

2. The role of biosimilars in the treatment of rheumatic diseases;Dörner;Ann Rheum Dis,2013

3. A randomised, double-blind, multicenter, parallel-group, prospective phase 1 study comparing the pharmacokinetics, safety and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study;Park;Ann Rheum Dis

4. American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials;Felson;Ann Rheum Dis,2011

Cited by 574 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness;Expert Opinion on Biological Therapy;2024-09-13

2. Efficacy and safety of biosimilar infliximab in bio-naïve patients with Crohn’s disease;Arab Journal of Gastroenterology;2024-08

3. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) (Version 4.1) – living guideline;Zeitschrift für Gastroenterologie;2024-08

4. Anti-TNFα in inflammatory bowel disease: from originators to biosimilars;Frontiers in Pharmacology;2024-07-24

5. Cost-Effectiveness of Biosimilars vs Leflunomide in Patients With Rheumatoid Arthritis;JAMA Network Open;2024-06-26